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Spinal and bulbar muscular atrophy (SBMA) is
caused by the polyglutamine androgen receptor
(polyQ-AR), a protein expressed by both lower motor
neurons and skeletal muscle. Although viewed as a
motor neuronopathy, data from patients and mouse
models suggest that muscle contributes to disease
pathogenesis. Here, we tested this hypothesis using
AR113Q knockin and human bacterial artificial chro-
mosome/clone (BAC) transgenic mice that express
the full-length polyQ-AR and display androgen-
dependent weakness, muscle atrophy, and early
death. We developed antisense oligonucleotides
that suppressed AR gene expression in the periphery
but not the CNS after subcutaneous administration.
Suppression of polyQ-AR in the periphery rescued
deficits inmuscleweight, fiber size, andgrip strength,
reversed changes in muscle gene expression, and
extended the lifespan of mutant males. We conclude
that polyQ-AR expression in the periphery is an
important contributor to pathology in SBMA mice
and that peripheral administration of therapeutics
should be explored for SBMA patients.
INTRODUCTION
Spinal and bulbar muscular atrophy (SBMA) is one of nine un-
treatable diseases caused by CAG/glutamine tract expansions.
In SBMA, a polyglutamine (polyQ) tract near the amino terminus
of the androgen receptor (AR) leads to hormone-dependent
protein unfolding and to the loss of lower motor neurons in
the brainstem and spinal cord of affected males (Lieberman
and Fischbeck, 2000). Clinical onset occurs in adolescence to
adulthood and is characterized initially by muscle cramps and
elevated serum creatine kinase (Katsuno et al., 2006b; Sperfeld
et al., 2002). These myopathic features commonly precede774 Cell Reports 7, 774–784, May 8, 2014 ª2014 The Authorsmuscle weakness, which inevitably develops as the disease
progresses and is most severe in the proximal limb and bulbar
muscles. As with all of the polyglutamine disorders, the mecha-
nisms that lead to selective neuronal dysfunction and degenera-
tion are poorly understood, and disease-modifying therapies are
currently unavailable.
Several general principles have emerged from the study of
SBMA model systems that guide our understanding of disease
pathogenesis. Binding of testosterone or dihydrotestosterone
to the polyQ-AR promotes ligand-dependent unfolding and
nuclear translocation of the mutant protein (Katsuno et al.,
2002; Takeyama et al., 2002). These steps are required for path-
ogenesis and underlie the occurrence of disease only in men.
The mutation leads to a partial loss of transactivation function
(Chamberlain et al., 1994; Irvine et al., 2000; Kazemi-Esfarjani
et al., 1995; Lieberman et al., 2002; Mhatre et al., 1993), and
while this may contribute to features of androgen insensitivity,
neuromuscular degeneration is mediated by a toxic gain of func-
tion conferred by protein unfolding. In SBMA, as in other CAG/
polyQ disorders, the mutant protein disrupts multiple down-
stream pathways, and toxicity likely results from the cumulative
effects of altering a diverse array of cellular processes including
transcription, RNA splicing, axonal transport, and mitochondrial
function (Katsuno et al., 2006a; Kemp et al., 2011; McCampbell
et al., 2000; Morfini et al., 2006; Ranganathan et al., 2009; Sze-
benyi et al., 2003; Yu et al., 2009). The existence of divergent
mechanisms of toxicity suggests that potential treatments tar-
geting a single downstream pathway are likely to be incomplete
or unsuccessful. In contrast, efforts to target the polyQ-AR as the
proximal mediator of toxicity by harnessing cellular machinery to
promote its degradation hold promise for therapeutic interven-
tion. Because the Hsp90-based chaperone machinery controls
proteostasis of the AR (Morishima et al., 2008; Thomas et al.,
2004, 2006; Wang et al., 2010), genetic and pharmacological
approaches to promote Hsp70-dependent ubiquitination have
been shown to facilitate degradation of the mutant protein
(Wang et al., 2013).
Insights into the mechanisms underlying selective neuromus-
cular degeneration in SBMA have come from the study of mouse
models. Previous analysis of AR113Q knockin mice suggested
that pathology arising in skeletal muscle contributes to the dis-
ease phenotype (Yu et al., 2006a). In these mice, denervation
and myopathy precede spinal cord pathology, consistent with
the notion that myopathy is an early disease manifestation
(Jordan and Lieberman, 2008). Supporting a role for muscle in
pathogenesis are data from transgenic mice that overexpress
wild-type (WT) AR only in skeletal muscle and show hormone-
dependent myopathy and motor axon loss (Johansen et al.,
2009; Monks et al., 2007). That muscle both contributes to the
SBMA phenotype and provides a therapeutic target is supported
by data showing diminished disease severity in polyQ-AR
transgenic mice with genetic overexpression of IGF-1 in skeletal
muscle (Palazzolo et al., 2009) or with peripheral IGF-1 adminis-
tration (Rinaldi et al., 2012).
Here, we test an alternative strategy to ameliorate toxicity in
mouse models of SBMA by suppressing polyQ-AR expression
using antisense oligonucleotides (ASOs). We use these com-
pounds to specifically target polyQ-AR expression in the periph-
ery. We demonstrate using two mouse models that peripheral
gene suppression of the polyQ-AR rescues deficits in muscle
weight, fiber size, and grip strength; reverses changes in muscle
gene expression; and extends lifespan of mutant males. We
conclude that polyQ-AR expression in the periphery is an impor-
tant contributor to pathology in SBMA mice and that peripheral
administration of therapeutics should be explored for SBMA
patients.
RESULTS
Subcutaneous ASO Suppresses PolyQ-AR Expression in
the Periphery but Not the Spinal Cord
We sought to define the contribution of peripherally expressed
polyQ-AR to the phenotype of SBMA mice and to determine
whether peripheral tissue is a therapeutic target. To accomplish
this, we suppressed AR expression by subcutaneous adminis-
tration of ASOs. Because these compounds do not cross the
blood-brain barrier (Geary, 2009; Yu et al., 2007), this strategy
selectively targeted AR in peripheral tissues such as skeletal
muscle. We developed 16-mer chemically modified ASO com-
plementary to human and mouse or human AR transcripts
(ASO1 and ASO2 respectively; Table S1). These 20,40-con-
strained ethyl (cEt) gapmer ASOs show increased stability,
tolerability, and potency upon in vivo administration (Seth
et al., 2009). Initial characterization demonstrated dose-depen-
dent suppression of human andmouse ARmRNAs in cell culture
by targeted, but not control, ASOs (Figure 1A). Similarly, subcu-
taneous administration of targeted, but not control, ASOs led to
dose-dependent suppression of AR mRNA and protein expres-
sion in skeletal muscle of WT male mice (Figures 1B and 1C).
Serum testosterone levels of these males exhibited modest
variability, and treatment with targeted ASOs did not result in a
significant alteration (Figure S1).
We used these compounds to determine the extent to which
suppressing peripheral expression of the polyQ-AR rescued the
phenotype of SBMA mice. This was accomplished using both
AR113Q knockin (Yu et al., 2006a; Yu et al., 2006b) and human
bacterial artificial chromosome/clone (BAC) fxAR121 transgenicmice (Cortes et al., 2014). Both of these models express the
full-length polyQ-AR under the regulation of its endogenous
promoter. These mice display a similar androgen-dependent
phenotype characterized by weakness, muscle atrophy, and
early death. In both models, subcutaneous administration of
ASOs decreased AR expression in skeletal muscle, but not
spinal cord. To determine the targeting efficacy and specificity
in skeletal muscle, BAC fxAR121 transgenic males were treated
with the human AR-targeted ASO2. Subcutaneous adminis-
tration of human AR-targeted ASO2, but not control ASO,
led to dose-dependent suppression of transgene expression
in skeletal muscle without affecting expression of the endoge-
nous mouse allele (Figure 1D). While treatment with ASO2
(50 mg/kg, twice weekly, starting at 11 weeks) specifically
suppressed transgene expression in skeletal muscle of BAC
transgenic mice, the human and mouse cross-reactive ASO1
suppressed both transgenic human AR and endogenous
mouse AR mRNA (Figure 2A), demonstrating target selectivity.
Quantitative real-time RT-PCR demonstrated >95% reduction
of human AR mRNA levels in skeletal muscle of treated males.
No significant change in mouse or human AR mRNA levels was
detected in brain or spinal cord of treated mice (Figure 2A), indi-
cating that subcutaneous administration selectively targeted
peripheral AR expression. The decrease of AR mRNA in muscle
was associated with comparable reduction in AR protein
immunoreactivity in skeletal muscle nuclei following treatment
(Figure 2B).
AR113Q knockin males express a hybrid humanized AR in
which most of mouse AR exon 1 has been replaced by human
sequence (Yu et al., 2006b). Therefore, we used ASO1, a human
and mouse AR cross-reactive ASO, to treat these mice. Subcu-
taneous administration of ASO1 (50 mg/kg, twice per week for
4 weeks and then once per week) or saline was initiated at
8 weeks and continued until 26 weeks. Treatment resulted in a
significant decrease in AR mRNA levels in quadriceps muscle,
but not spinal cord (Figure 2C). This decrease in AR expression
was long-lived, as partial mRNA reduction was detected in skel-
etal muscle harvested from mice at 36 weeks of age, 10 weeks
after the termination of treatment; by 46 weeks of age (20 weeks
posttreatment washout), ARmRNA levels in muscle approached
those of saline-treated controls. Similarly, sustained suppres-
sion of transcripts by ASOs has been reported in skeletal muscle
of myotonic dystrophy mice (Wheeler et al., 2012). Knockdown
of AR mRNA levels in muscle was associated with a 90%
decrease in AR protein levels (Figure 2D). We observed a slow
recovery in AR protein levels in muscle after the termination of
treatment, with expression remaining 80% lower than controls
at 10 weeks posttreatment and 65% lower than controls at
20 weeks posttreatment (age 46 weeks). In contrast, AR mRNA
and protein expression in spinal cord were not significantly
altered by peripheral ASO delivery.
Peripheral PolyQ-AR Suppression Rescues Disease in
SBMA Mice
Significant amelioration of disease phenotype following AR
gene suppression in the periphery was observed in both
SBMA mouse models. BAC fxAR121 mice exhibited an age-
dependent loss of grip strength and body mass (Figures 3ACell Reports 7, 774–784, May 8, 2014 ª2014 The Authors 775
Figure 1. Dose-Dependent Suppression of AR Expression by Targeted ASOs
(A) Human umbilical vein endothelial cells (top) and mouse brain endothelial cells (bEnd.3) cells (bottom) were electroporated in the presence of AR-targeted or
control ASOs at the indicated concentrations. Relative ARmRNA levels were determined after 16 hr and are reported as mean ± SD. UTC, untransfected control.
(B and C) Wild-type male mice received subcutaneous injections of ASO1, control ASO, or saline from 6 to 14 weeks (n = 3 per group). Animals were treated with
ASO1 or control ASO at 50 mg/kg per week, or with two lower doses of ASO1 (25 mg/kg per day 3 3 days, then 12.5 mg/kg per week; or 17.5 mg/kg per day3
3 days, then 10 mg/kg per week). Quadriceps muscle was harvested at 14 weeks for analysis of AR expression.
(B) Relative AR mRNA levels (mean ± SEM). *p < 0.05, ***p < 0.001.
(C) AR protein as detected by immunoprecipitation and western blot.
(D) BAC fxAR121males (n = 4 per group) received subcutaneous injections of control ASO (25mg/kg per week), ASO2 (25, 12.5, or 6.25mg/kg per week), or saline
from 7–15 weeks. Quadriceps muscle was harvested 48 hr after the final dose and analyzed for human and mouse ARmRNA levels. Data are mean ± SD. ***p <
0.001 compared to saline treatment.and 3B). These deficits were partially rescued in a dose-depen-
dent manner by subcutaneous administration of ASO2, but not
control ASO (Figures 3A and 3B). Higher-dose treatment with
ASO2 (50 mg/kg per week), starting at an asymptomatic age
(6 weeks) and continuing for 4 weeks, completely ameliorated
the loss of grip strength and body mass in transgenic males
(Figures 3C and 3D). This was associated with rescue of lean
body mass as measured by MRI (Figure 3E). BAC fxAR121
males treated with ASO2 showed a dose-dependent extension
of lifespan (Figure 4A). Similarly, treatment of AR113Q knockin
males with ASO1 starting at 8 weeks resulted in a significant
extension of lifespan (Figure 4B), without altering serum testos-
terone levels (Figure S2).
To further assess the clinical implications and therapeutic
relevance of this strategy, we initiated treatment with ASO2 in
a separate cohort of BAC fxAR121 mice at 11 weeks, an age776 Cell Reports 7, 774–784, May 8, 2014 ª2014 The Authorsat which these males begin to exhibit diminished grip strength
and bodymass, as shown in Figure 3. Subcutaneous administra-
tion of ASO2 for durations varying from 2 to 8 weeks resulted in a
significant increase in survival that reflected the length of treat-
ment (Figure 5A). Furthermore, we detected a significant deficit
in grip strength only in those animals treated with ASOs for the
shortest duration (Figure 5B). These data indicate that therapeu-
tic benefits from peripherally administered ASOs are dependent
upon total treatment dose and are detected even when initiated
at the onset of symptoms.
ASO treatment rescued polyQ-AR-mediated pathology in
skeletal muscle of both SBMA mouse models. AR113Q knockin
males showed skeletal muscle atrophy at 26 weeks of age, and
both tibialis anterior muscle mass (Figure 6A) and quadriceps
muscle fiber size (Figure 6B) were increased by ASO1 treatment
starting at 8 weeks. This rescue of muscle mass was maintained
Figure 2. Subcutaneous ASO Administration
Suppresses AR Expression in Muscle but
Not Spinal Cord
(A) The 11-week-old BAC fxAR121 males (n = 4 per
group) received subcutaneous injections of ASOs
(50 mg/kg, twice weekly) or saline for 4 weeks.
Quadriceps muscle, brain, and spinal cord were
harvested 48 hr after the final dose and analyzed for
human (left) and mouse (right) AR mRNA levels.
Data are mean ± SD. ND, not detected. ***p < 0.001
compared to saline treatment.
(B) Wild-type (WT; left) and BAC fxAR121 males
(middle and right) received subcutaneous injections
of ASO1 (50 mg/kg weekly, starting at 6 weeks) or
saline for 4 weeks. The external urethral sphincter
muscle was harvested and stained for AR by
immunohistochemistry. Scale bar, 15 mm.
(C and D) AR113Q (n = 10 per group) and WT (n = 3
per group) males received subcutaneous injections
of ASO1 (50 mg/kg, twice weekly for 4 weeks, and
then once weekly) or saline, from 8 until 26 weeks.
Quadriceps muscle and spinal cord were harvested
at the indicated ages and analyzed for (C) ARmRNA
(mean ± SEM) and (D) protein by immunoprecipi-
tation and western blot. ***p < 0.001; n.s., not sig-
nificant.in mice at 36 weeks of age, 10 weeks after termination of treat-
ment, but was lost at 46 weeks, or 20 weeks off treatment.
These findings paralleled changes in polyQ-AR expression (Fig-
ures 2C and 2D). ASO1 treatment also diminished the frequency
of AR immunoreactive intranuclear inclusions in skeletal muscle
nuclei of knockin males (Figure 6C). These inclusions were not
detected in quadriceps muscle of treated males at 26 weeks
and were present in only occasional nuclei of the levator ani/bul-Cell Reports 7, 774bocavernosus (LA/BC) muscle. Because
the LA/BC expresses high levels of AR
(Jordan et al., 1997; Monks et al., 2004),
intranuclear inclusions were frequent in
saline-treated AR113Q males, and their
persistence in some nuclei after ASO
treatment indicated that a subpopulation
was long-lived. Similar findings have
been observed following ASO treatment
of Huntington disease mice (Kordasiewicz
et al., 2012). As with the LA/BC muscle,
the external urethral sphincter (EUS)
muscle expressed high levels of AR (data
not shown) and exhibited more severe
and early-onset atrophy than quadriceps
muscle (Figure 6D). In BAC fxAR121
males, ASO2 treatment rescued muscle
fiber size in both EUS and quadriceps
muscles (Figure 6D). In both BAC
fxAR121 and AR113Q males, ASO treat-
ment also diminished the levels of acetyl-
choline receptor-a subunit and myogenin
mRNAs, genes that are induced following
denervation and are upregulated inSBMA mice (Figures 6E and 6F). In both models, this rescue
was partially maintained 6–10 weeks posttreatment.
Finally, to further assess the relative contribution of peripheral
polyQ-AR expression to the disease phenotype, we directly
compared the efficacy of peripheral versus intraventricular
versus combined administration of ASOs in BAC fxAR121
mice. For these experiments, we used a third AR-targeted
ASO, ASO3, whose chemistry is well tolerated by mice following–784, May 8, 2014 ª2014 The Authors 777
Figure 3. Dose-Dependent Rescue of Grip Strength and Body Mass in BAC fxAR121 Males by ASO2
(A and B) BAC fxAR121 or wild-type (WT) males (n = 10 per group) were treated with increasing doses of ASO2 (6.25–25 mg/kg per week), control ASO, or saline
from 7 until 15 weeks. Grip strength (A) and body mass (B) are reported as mean ± SD. Grip strength and body mass of transgenic (Tg) mice treated with ASO2 at
12.5 and 25mg/kg per week are different from saline treated in weeks 15–21 (p < 0.05). Tgmice treatedwith saline show decreased grip strength compared toWT
mice in weeks 11–21 (p < 0.05 by ANOVA) and decreased body mass in weeks 12–21 (p < 0.05 by ANOVA).
(C and D) BAC fxAR121 or WT males (n = 7–10 per group) received subcutaneous injections of ASO2 (50 mg/kg per week, starting at 6 weeks) or saline for
4 weeks. Age-dependent changes in (C) grip strength and (D) body mass are reported as mean ± SD. In (C), **p < 0.01, ***p < 0.001 compared to saline-treated
BAC fxAR121 starting at week 13 by ANOVA. In (D), p < 0.05 for ASO2 versus saline-treated Tg mice from weeks 14 to 16 by ANOVA.
(E) BAC fxAR121 or WT males (n = 9–10 per group) received subcutaneous injections of ASO2 (50 mg/kg per week, starting at 6 weeks) or saline for 4 weeks.
MRI was performed at 16 weeks and used to determine lean body mass. Data are mean ± SD. ***p < 0.001 compared to saline-treated BAC fxAR121 by
ANOVA.intraventricular injection (Table S1). We found that a single intra-
ventricular administration of ASO3 (100 mg at 8 weeks) dimin-
ished human polyQ-AR mRNA levels in lumbar spinal cord by
60% (Figure 7A). This effect was long-lived and was detected
up to 8 weeks after intraventricular administration. Notably,
intraventricular delivery did not alter polyQ-AR mRNA levels in
quadriceps muscle, which were only diminished in mice
receiving subcutaneously delivered ASO2 (Figure 7A). In order
to increase the likelihood of detecting an additive benefit from
intraventricular administration, we limited the subcutaneous
dose to 12.5 mg/kg per week. At this dose, peripheral ASO2
diminished polyQ-AR mRNA expression in muscle by 60%–
70% (Figure 7A) and partially rescued grip strength and survival
(Figures 7B and 7C). A single bolus intraventricular administra-
tion of ASO3 did not alter grip strength or survival in BAC
fxAR121 mice, despite lowering polyQ-AR mRNA expression778 Cell Reports 7, 774–784, May 8, 2014 ª2014 The Authorsin lumbar spinal cord (Figures 7B and 7C). Furthermore, com-
bined intraventricular and subcutaneous delivery of ASO was
no more effective than subcutaneous delivery alone at rescuing
the disease phenotype (Figures 7B and 7C). Altogether, we
conclude that peripheral delivery of targeted ASOs suppresses
AR expression in skeletal muscle, but not spinal cord, and that
this treatment rescues deficits in grip strength, body weight,
survival, and skeletal muscle atrophy in two mouse models of
SBMA.
DISCUSSION
Our data demonstrate that polyQ-AR suppression outside the
CNS is sufficient to ameliorate the disease phenotype in two
independent mouse models of SBMA. This strategy is distinct
from prior efforts that have focused on targeting polyQ-AR
Figure 4. Peripheral PolyQ-AR Suppression Rescues Survival of SBMA Mice
(A) Survival of BAC fxAR121 or wild-type (WT) males (n = 10 per group) treated with increasing doses of ASO2 (6.25–25 mg/kg per week), control ASO, or saline
from 7 until 15 weeks. The dark blue/black line depicts overlapping survival curves of WT (saline- and ASO2-treated) and transgenic (Tg) mice treated with ASO2
at 25 mg/kg per week.
(B) Survival of AR113Q (n = 10 per group) andWT (n = 3 per group) males receiving subcutaneous injections of ASO1 or saline from 8 until 26 weeks (as described
in Figure 1C). The red line depicts overlapping survival of WTmales treated with saline or ASO1. ASO1 treatment significantly extended lifespan of AR113Qmales
(p = 0.016).toxicity within motor neurons. We show that subcutaneous
delivery of ASOs suppresses polyQ-AR expression in skeletal
muscle, but not spinal cord, and this rescues deficits in muscle
weight, fiber size, and grip strength; reverses changes in mus-
cle gene expression; and extends lifespan of mutant males.
Complementary analysis of BAC fxAR121 mice following ge-
netic deletion of the floxed allele specifically in skeletal muscle
corroborates our findings (Cortes et al., 2014) and confirms that
skeletal muscle is the critical target tissue for this therapeutic
intervention.
Our data demonstrate an unexpectedly important contribu-
tion of skeletal muscle to the SBMA phenotype. The occur-
rence of non-cell-autonomous neurotoxicity is an increasingly
recognized component of degenerative disorders (Ilieva
et al., 2009). For motor neuron diseases, models of familial
amyotrophic lateral sclerosis caused by mutant superoxide
dismutase 1 have uncovered contributions to pathogenesis
from astrocytes, oligodendrocytes, and microglia (Boille´e
et al., 2006; Di Giorgio et al., 2007; Kang et al., 2013; Lee
et al., 2012; Yamanaka et al., 2008). Similarly, models of spinal
muscular atrophy have demonstrated important contributions
from skeletal muscle (Cifuentes-Diaz et al., 2001; Mutsaers
et al., 2011) and have shown efficacy of peripheral gene target-
ing using ASOs to regulate SMN2 mRNA splicing (Hua et al.,
2011). For SBMA, the findings reported here and by Cortes
et al. (2014) indicate that peripheral expression of the polyQ-
AR in skeletal muscle underlies degenerative changes in the
neuromuscular system. This correlates with much higher
expression of polyQ-AR protein in skeletal muscle than in spi-
nal cord of SBMA patients (Tanaka et al., 1999). Although the
precise mechanism by which skeletal muscle influences dis-
ease remains to be defined, impaired trophic support from
SBMA muscle may contribute to pathogenesis. Diminished
expression of several trophic factors by skeletal muscle in
SBMA mouse models has been demonstrated previously,
including neurotrophin-4, glial-derived neurotrophic factor,and vascular endothelial growth factor (Sopher et al., 2004;
Yu et al., 2006a). Because these and other muscle-derived
factors support innervating neurons, their decreased expres-
sion could impact the function and viability of lower motor
neurons expressing the polyQ-AR as well as their resistance
to polyQ toxicity (Jordan and Lieberman, 2008). This model
of pathogenesis is consistent with the well-established role
of skeletal muscle in maintaining motor neurons (Jessell and
Sanes, 2000) and suggests a mechanism whereby the neuro-
muscular system may be especially vulnerable to toxicity
from the polyQ-AR.
The therapeutic benefits documented here following periph-
eral administration of ASOs provide a compelling rationale for
exploring treatments targeted to skeletal muscle in SBMA
patients. However, several important questions remain as we
work toward translating these findings to patients. The optimal
therapeutic dose for alleviating proteotoxicity while maintaining
beneficial anabolic effects of AR on skeletal muscle remains to
be defined. Figures 1B and 1C show dose-dependent effects
on AR mRNA and protein levels over the therapeutic range of
ASOs used in these studies, and future work will help optimize
this approach to treatment. Importantly, no target-related
adverse findings were observed in either WT or SBMA mice
following ASO treatment, demonstrating that this treatment
approach is feasible, beneficial, and lacking untoward conse-
quences. We recognize that the loss of anabolic effects of AR
on skeletal muscle may be more pronounced in SBMA patients
than in mice and could necessitate concurrent trophic factor
support. Furthermore, we acknowledge that both mouse
models exhibit marked skeletal muscle pathology and do not
display motor neuron loss, a limitation of the available model
systems. Nonetheless, the observations reported here estab-
lish a foundation for developing disease-modifying therapies
targeted to skeletal muscle and demonstrate the important
contribution of peripherally expressed polyQ-AR to SBMA
pathogenesis.Cell Reports 7, 774–784, May 8, 2014 ª2014 The Authors 779
Figure 5. Phenotype Rescue Is Dependent upon Treatment Duration
and Is Observed when Treatment Begins at Symptom Onset
BAC fxAR121 or wild-type (WT) males received subcutaneous injections of
ASO2 or saline starting at 11 weeks. Mice were treated (n = 6–10 per group) for
8weekswith 50mg/kg perweek or for 2, 4, or 8weekswith 25mg/kg per week.
(A) Survival of BAC fxAR121 (Tg) is significantly extended by ASO treatment
(p < 0.01). The light-blue line depicts overlapping curves for WT and Tg mice
treated with ASO2 at 50 mg/kg per week for 8 weeks and Tg mice treated with
ASO2 at 25 mg/kg per week for 8 weeks.
(B) Grip strength at 22 weeks, 4 weeks after final treatment (n = 3–5 per group,
except saline-treated BAC fxAR121, where only one mouse survived at this
time point).
Data are mean ± SD. **p < 0.05 compared to saline-treated WT males.EXPERIMENTAL PROCEDURES
Mice
Derivation of AR113Q mice with a targeted Ar allele containing 113 CAG
repeats in exon 1 was described previously (Yu et al., 2006b). Briefly, mice
were generated by recombining a portion of human exon 1 (amino acids 31–
484) with the mouse Ar gene in CJ7 embryonic stem cells. Male chimeras
were mated with C57BL/6J females, and females heterozygous for the tar-
geted Ar allele were backcrossed to C57BL/6J ten or more generations.
BAC fxAR121 mice were derived as described elsewhere (Cortes et al.,
2014). Male offspring housed in SPF facilities and maintained on a constant
12 hr light/12 hr dark cycle were used in this study. Subcutaneous administra-
tion of ASOs or saline was performed according to the indicated treatment
schedules. For intraventricular administration, 8-week-old mice were anaes-
thetized with 2% isoflurane and held by the head in a stereotaxic instrument.
A total of 10 ml of ASO (100 mg) in saline was injected into the right lateral
ventricle. The coordinates for injection were 0.3 mm anterior, 1.0 mm lateral,
and 3.0 mm ventral from the bregma, as described previously (Sahashi
et al., 2013). Body composition was measured by an Echo MRI system
(Echo Medical System). Procedures involving mice were approved by the
University of Michigan Committee on Use and Care of Animals, in accord
with the NIH Guidelines for the Care and Use of Experimental Animals, or by
the Isis Pharmaceuticals Institutional Animal Care and Use Committee.
Oligonucleotides
A series of uniform chimeric 16-mer phosphorothioate oligonucleotides con-
taining cEt groups at positions 1–3 and 14–16 targeted to mouse or human780 Cell Reports 7, 774–784, May 8, 2014 ª2014 The AuthorsAR and a control ASO (Table S1) were synthesized and purified on an
automated DNA synthesizer using phosphoramidite chemistry, as previously
described (Koller et al., 2011). All ASOs were dissolved in PBS and filtered
before injections were performed.
RNA Analysis
Total RNA was isolated from tissues of AR113Q knockin males with TRIzol
(Invitrogen) according to the manufacturer’s instructions. RNA (1 mg) was
used to synthesize cDNAwith the high-capacity cDNA archive kit (Applied Bio-
systems). Gene-specific primers (18S rRNA, 4310893E;Ar, Mm00442688_m1;
a-acetylcholine receptor, Mm00431627_m1; myogenin, Mm00446194_m1)
were purchased from Applied Biosystems, and analyses were performed in
duplicate using 10 ng aliquots of cDNA on an ABI 7500 Real Time PCR system.
Relative expression levels were calculated by comparison with the expression
of 18S rRNA.
BAC fxAR121 tissues were homogenized in a guanidine isothiocyanate
solution (Invitrogen) supplemented with 8% 2-mercaptoethanol (Sigma-
Aldrich). Total RNA was prepared according to the PureLink Total RNA Puri-
fication Kit (Invitrogen). The quantitative RT-PCR analyses were done using
a StepOne Real-Time PCR System (Applied Biosystems). The sequences
of primers and probe used were as follows: mouse androgen receptor: for-
ward: 50-CAGCAGAAACGATTGTACCATTG-30, reverse: 50- GCTTACGAGCT
CCCAGAGTCA-30, probe: 50-Fam- AAAATTGCCCATCTTGTCGTCTCCGG-
Tamra-30; human androgen receptor: forward: 50-GCCCCTGGATGGATAGC
TACT-30, reverse: 50- CCACAGATCAGGCAGGTCTTC-30, probe: 50-Fam-
ACTGCCAGGGACCATGTTTTGCCC-Tamra-30; mouse cholinergic receptor
nicotinic, alpha polypeptide1 (Life Technologies) Mm00431627_m1; mouse
myogenin (Life Technologies) Mm00446194_m1. PCR results were normal-
ized to total RNA measure by Quant-iT RiboGreen RNA reagent (Molecular
Probes).
Immunoprecipitation and Western Blot
Muscle and spinal cord were homogenized in RIPA buffer containing com-
plete protease inhibitor cocktail (Roche) using a motor homogenizer
(TH115, OMNI). Lysates were incubated on a rotator at 4C for 1 hr and
then precleared by centrifugation at 13,0003 g for 10 min at 4C. Protein con-
centration was determined by bicinchoninic acid protein assay (Pierce). Pro-
tein lysates (500 mg) were incubated with AR antibody (Millipore, PG-21) or
rabbit immunoglobulin G (Santa Cruz Biotechnology) overnight at 4C and
then with protein A beads (Santa Cruz) for 1 hr at 4C. Beads were washed
and the eluate was resolved by 7.5% SDS-PAGE and then transferred to
nitrocellulose membranes (Bio-Rad). Blots were probed with AR antibody
(Santa Cruz), and proteins were visualized by chemiluminescence (Thermo
Scientific).
Muscle Histology and Immunofluorescence Staining
AR113Q skeletal muscle was frozen in isopentane prechilled by liquid nitrogen,
sectioned at 5 mm with a cryostat, and stained with hematoxylin and eosin
(H&E). For immunofluorescence, frozen sections were stained with an AR anti-
body (Santa Cruz) and a secondary antibody conjugated to Alexa Fluor 594
(Invitrogen). Confocal imageswere capturedwith a Zeiss LSM510microscope
and a water-immersion lens (363).
BAC fxAR121 muscle was fixed with 10% neutral buffered formalin,
embedded in paraffin, and sectioned at 4 mm. Antigen retrieval was performed
by boiling in Thermo citrate buffer (pH 6.0) (Thermo Scientific) for 20min. Slides
were blocked by donkey serum (Jackson ImmunoResearch) for 30 min. The
primary antibody (AR: sc-816, Santa Cruz; laminin: ab11575, Abcam) was
applied and incubated at room temperature for 1 hr. After three washes in
PBSwith Tween 20, slides were incubated with donkey anti-rabbit horseradish
peroxidase (Jackson ImmunoResearch) at 1:200 for 30 min, then developed
with DAB and counterstained with hematoxylin (Surgipath), dehydrated, and
mounted.
Muscle Fiber Size Quantification
The cross-sectional diameter of BAC fxAR121muscle fibers wasmeasured by
image analysis after staining with laminin to highlight the muscle membrane.
The minimal diameter of each muscle fiber was quantified by the muscle fiber
Figure 6. Peripheral ASO Administration Rescues Muscle Atrophy and Gene Expression Changes
(A) Tibialis anterior (TA) muscle mass at 26 weeks from AR113Q or wild-type (WT) males treated with ASO1 or saline (treated as described in Figure 1C) or
posttreatment at age 36 or 46 weeks. Data are mean ± SEM. *p < 0.05; n.s., not significant.
(B) Quadriceps muscle fiber size distribution (left panel) and mean ± SEM (right panel) from AR113Q or WT males at 26 weeks, treated as described in Figure 1C.
***p < 0.001.
(C) AR immunofluorescence (red) of quadriceps and levator ani/bulbocavernosus (LA/BC)muscles of AR113Q andWTmales at 26 weeks, treated as described in
Figure 1C. DAPI stains nuclei. Scale bar, 10 mm.
(D) External urethral sphincter (upper panel) and quadriceps muscle (lower panel) fiber size were determined from BAC fxAR121 males (n = 4 per group) that
received subcutaneous ASO2 (50 mg/kg per week, starting at 6 weeks) for 4 weeks. Muscle was harvested from transgenic (Tg) and WT males at 10 and
16 weeks. Data are mean ± SD. *p < 0.05.
(E) BAC fxAR121males (n = 3–4 per group) received subcutaneous injections of ASO2 (50mg/kg per week, starting at 6 weeks) or saline for 4 weeks. Quadriceps
muscle was harvested at 10 and 16 weeks, and AChR-a and myogenin mRNA expression determined. Data are mean ± SD. **p < 0.01, ***p < 0.001.
(F) AChR-a and myogenin mRNA expression in quadriceps muscle of AR113Q or WT males at 26 weeks (treated as described in Figure 1C) or following
termination of treatment at 36 weeks. Data are mean ± SEM. **p < 0.01, *p < 0.05.algorithm (Indica Lab). Frozen sections of AR113Qmuscle (5 mm) were stained
by H&E, and digital images were captured using a Zeiss Axioplan 2 imaging
system. The area of each muscle fiber was defined using Adobe Photoshop
CS4, and the pixel number was converted to mm2 according to scale, as
described elsewhere (Yu et al., 2011). A total of 100 adjacent fibers from
each section were measured.
Grip Strength
Forelimb strength of BAC fxAR121 mice was measured with a digital grip
strength meter that records the maximal strength an animal exerts while tryingto resist an opposing pulling force. In brief, each mouse was allowed to grasp
the metal rail with its forelimbs and gradually pulled backward in the horizontal
plane. The highest reading from five to ten consecutive trials was recorded
by a four-channel transducer (TBM4M, World Precision Instruments) using
labScribe2 software (Transonic Systems).
Testosterone Levels
Serum was collected by cardiac puncture. Testosterone levels were deter-
mined by radioimmunoassay by the Ligand Assay and Analysis Core Facility
at the University of Virginia Center for Research in Reproduction.Cell Reports 7, 774–784, May 8, 2014 ª2014 The Authors 781
Figure 7. Intraventricular ASO Administration Does Not Provide Added Benefit to BAC fxAR121 Mice Receiving Peripheral ASO
(A) BAC fxAR121micewere dosed as indicated with saline (sal), intraventricular (ICV) ASO3, or control (cnl) ASO (100 mg at 8weeks) and subcutaneous (SQ) ASO2
(12.5 mg/kg per week, starting at 8 weeks). Spinal cord and quadricepsmuscle were harvested 4 or 8 weeks following ICV administration and analyzed for human
AR mRNA levels. Data (mean ± SEM) are reported relative to mice receiving ICV and SQ saline (n = 4 per group). ***p < 0.001.
(B and C) Wild-type (WT) or BAC fxAR121 males (n = 8–10 per group) were treated as indicated with saline (sal), intraventricular (ICV) ASO3, or control (cnl) ASO
(100 mg at 8 weeks) and subcutaneous (SQ) ASO2 (12.5 mg/kg per week, starting at 8 weeks). Age-dependent changes in grip strength (B) and survival (C) are
shown. Data are mean ± SEM.Statistics
Statistical significance was assessed by an unpaired Student’s t test (for pair-
wisecomparisons)orbyone-wayANOVAwithNewman-Keulsmultiplecompar-
ison test or Tukey’s post hoc test (for multiple comparisons). The distribution of
muscle fiber size was analyzed by Mann-Whitney test. Effects on survival were
assessedby log-rankanalysis. All statisticswasperformedusingPrism5or 5.04
(GraphPad Software). p values less than 0.05 were considered significant.
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